A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)

BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the agent would have greater antitumor activity compared with cetuximab in recurrent or metastatic (R/M) head and neck squamo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Seiwert, T. Y., Fayette, J., Cupissol, D., del Campo, J. M., Clement, P. M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., Cohen, E. E. W.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143093/
https://ncbi.nlm.nih.gov/pubmed/24928832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu216
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires